FDA monitoring failures cited in nearly a third of pharmaceutical warning letters and rising, according to Eupry
RALEIGH, N.C., June 23, 2026 /PRNewswire/ -- Analysis: Monitoring-related enforcement actions grew nearly 200% between 2021 and 2025, according to a review of 3,286 FDA warning letters A review of 3,286 FDA warning letters has found that nearly one in three pharmaceutical CGMP warning...
RALEIGH, N.C., June 23, 2026 /PRNewswire/ -- Analysis: Monitoring-related enforcement actions grew nearly 200% between 2021 and 2025, according to a review of 3,286 FDA warning letters A review of 3,286 FDA warning letters has found that nearly one in three pharmaceutical CGMP warning...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.